Niagen Bioscience, a global authority in the science of NAD+ (nicotinamide adenine dinucleotide), has announced the formal renaming of its widely recognized "ChromaDex External Research Program" to the "Niagen Research Program."
This move follows the company's strategic name change from ChromaDex to Niagen Bioscience and is designed to focus efforts on advancing the understanding and application of NAD+ through its flagship ingredient, Niagen.
The program is a core initiative for the company to consolidate its scientific leadership.
Since its inception, the program has supported over 300 research collaborations globally and has facilitated the publication of more than 45 human clinical studies on Niagen.
Over 90% of these studies were initiated and funded by independent investigators, underscoring the high credibility of the research.
Through this program, researchers from leading institutions such as the Mayo Clinic, the National Institutes of Health, Harvard University, and the University of Cambridge can apply to obtain Niagen research materials for in-depth exploration into the biological mechanisms of NAD+.
Niagen Bioscience CEO Rob Fried stated
"The renaming of the Niagen Research Program reflects both the maturity of the scientific research and the scale and depth with which the global research community is driving this field forward. As interest in NAD+ grows, credible science, rigorous clinical research, and responsible communication are more important than ever."
The program's areas of support have expanded into cutting-edge fields of NAD+ biology.
Beyond traditional areas such as cellular energy metabolism, cardiovascular health, and cognitive function, the program is actively exploring new directions like peripheral artery disease and ataxia-telangiectasia, a rare orphan disease.
Recently, the program's focus has also covered skin aesthetics science, immune function and inflammatory responses, and the development of injectable-grade pharmaceutical Niagen.
Additionally, the company has launched the "Niagen Bioscience Trainee Grant Program," which will annually award three $10,000 grants to graduate students and postdoctoral researchers focused on areas such as exercise performance, recovery, fatigue, and adaptation, aiming to cultivate the next generation of NAD+ scientific talent.
On the financial front, the company reported net sales of $31.5 million for the first quarter of fiscal year 2026, with gross margin improving to 63.5% and net profit reaching $6.3 million, demonstrating strong operational performance and providing a solid foundation for continued investment in scientific research and innovation.
Comments